Spondyloarthritis & psoriatic arthritis
Impact of tumour necrosis factor-α inhibitors on non-invasive indices of hepatic steatosis and fibrosis in patients with ankylosing spondylitis
Authors' conclusion
TNF-α inhibitors may have a neutral impact on hepatic steatosis, but a negative impact on hepatic fibrosis indices
Study context
- Population
- Patients with ankylosing spondylitis (AS) treated with TNFiTNFi for median 8.1 months (IQR 6.5–11.3)
- Participants
- 52 patients
- Exposure
- Baseline vs endpoint
- Outcome
- Change in non-invasive indices of hepatic steatosis (HSI) and fibrosis (FIB-4, APRI, BARD)
- Follow-up
- After at least 6 months of treatment
Methodological detailsbefore–after comparison
- Before–after comparison
Main finding
As reported in the abstract
Non-invasive indices of hepatic steatosis and fibrosis
- FIB-4 increased from 0.64 ± 0.23 to 0.83 ± 0.48
- p < 0.001
- Aminotransferase to platelet ratio index (APRI) increased from 0.16 ± 0.06 to 0.23 ± 0.13
- p < 0.001
Observational data: associations, not effects.
Original publication
Impact of tumour necrosis factor-α inhibitors on non-invasive indices of hepatic steatosis and fibrosis in patients with ankylosing spondylitis. Scand J Rheumatol. Published 3 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →